MedTrace Logo

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

NCT00283543 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-10-31

No results posted yet for this study

Summary

To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and radiation with Temozolomide

Conditions

  • Newly Diagnosed Supratentorial Malignant Glioma

Interventions

DRUG

Gliadel Wafer

DRUG

Temozolomide

PROCEDURE

Limited field radiation

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • Kentuckiana Cancer Institute

    lead OTHER

Principal Investigators

  • Renato V. LaRocca, MD · Kentuckiana Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283543 on ClinicalTrials.gov